Drs. Abdul Hamood, Garth James, and Paul Stoodley discuss gaps in evidence for standardized methodological approaches of biofilm models, which can lead to disparities between testing conditions.

This webcast reviews the latest clinical evidence with omega-3 fatty acids for the prevention of cardiovascular events in high-risk patients

Key Insights: Mastering Clinical Challenges and Emerging Therapies in IBD 2018

This webcast examines optimal therapies for concurrent psoriasis and comorbidity treatment while considering possible side effects and drug-drug interactions.

Dr. Joel M. Gelfand reviews the latest data regarding the pathogenesis of psoriasis (PsO) and the contribution of IL-23/Th17 signaling pathways to disease state, and discusses personalized treatment plans for patients with moderate-to-severe PsO that successfully incorporate both current and emerging therapies.

Dr. John Stone discusses best practices for integrating the latest clinical evidence surrounding new and emerging targeted therapies into optimal strategies for the long-term management of giant cell arteritis (GCA).

Learn about the latest clinical evidence surrounding new and emerging PV-targeted therapies with respect to mechanisms of action, efficacy, and safety for informed therapeutic selection.

Dr. Vibeke Strand discusses the mechanism of action of JAK inhibitors and examines the efficacy, safety, and adverse events associated with this class of small molecule therapeutics.

This webcast outlines the current understanding of EGPA pathophysiology and the resultant implications for targeted therapy, and examines the clinical efficacy and safety data surrounding current and emerging targeted therapies.

This webcast discusses current treatment barriers, new and emerging agents, and guideline recommendations into comprehensive, evidence-based treatment plans for psoriatic arthritis.